Principal Scientist

Could argenx SE (argx)'s global scale give it an edge over Zai Lab Limited American Depositary Shares (ZLAB)? Published on August 20, 2026 at 6:27 pm by laiba immad in hedge funds, news. Zai Lab Limited American Depositary Shares (NASDAQ:ZLAB) and argenx SE (NASDAQ:ARGX) announced positive topline results on August 17 from their Phase 3 ALKIVIA study evaluating VYVGART Hytrulo in adults with autoimmune myositis. In the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population, patients treated with efgartigimod achieved a statistically significant, 15.4-point greater improvement in mean Total Improvement Score (TIS) over placebo at Week 52. Improvements were sustained from Week 4 onward, even through steroid tapering. In IMNM, the primary endpoint was met with a 14.8-point improvement over placebo, while DM showed a similar 14.5-point benefit, though statistical significance was missed in that smaller cohort. On August 17, William Blair noted that the results boosted confidence in Vyvgart's path in DM, sending ARGX shares up 15% to an all-time high. On August 18, RBC Capital raised its price target on Argenx to $1,100 from $1,025, calling the IMNM data a "slam dunk" and projecting rapid commercial uptake given the 20,000 U.S. patient population. Financial performance: scale vs. Regional licensing. argenx SE (NASDAQ:ARGX) and Zai Lab Limited American Depositary Shares (NASDAQ:ZLAB) share clinical success through an exclusive licensing agreement covering Greater China, but their financial profiles remain significantly different in scale and profitability. ARGX delivered blockbuster Q2 2026 results driven by strong global VYVGART momentum, with net product sales reaching $1.516 billion, up 60% year over year. Total operating income reached $1.542 billion, resulting in operating profit of $494 million and net income of $472 million. The company also maintained a strong balance sheet with $5.2 billion in cash and current financial assets. ZLAB, by contrast, continues to operate as a developing commercial partner with substantially higher cash-burn requirements. Q2 2026 revenue totaled $106.3 million, down 3% year over year, while net product revenue reached $105.8 million. Rising R&D expenses of $61.8 million and SG&A expenses of $72.9 million contributed to an operating loss of $76.5 million and a net loss of $50.8 million. Zai Lab ended the quarter with $717.5 million in cash and short-term investments, highlighting the substantial financial gap between the two partners. Bull and bear cases. Argenx's bull case is supported by VYVGART's growing global presence across generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), and autoimmune myositis. Its $5.2 billion liquidity position provides substantial financial capacity to expand into additional FcRn-mediated indications without significant dilution risk. However, the bear case centers on the company's heavy reliance on VYVGART as its primary commercial growth engine, leaving the stock vulnerable to FDA delays or regulatory pushback surrounding separate trials for dermatomyositis (DM). Zai Lab's bull case is driven by its strong regional footprint in Greater China and an expanding portfolio that includes VYVGART, KarXT, and TIVDAK. Sequential revenue growth of 11% indicates improving commercial stability as the company scales its product portfolio. On the downside, Zai Lab continues to face persistent losses, including a $50.8 million net loss in Q2, while established products such as ZEJULA face commercial pressure from increasing generic competition in China. Insider monkey's hedge fund data analysis. Institutional sentiment heading into 2026 showed moderate institutional trimming for both names. Zai Lab Limited American Depositary Shares (NASDAQ:ZLAB) held 14 hedge fund positions in Q1 2026 (down from 17 in Q4 2025), with RA Capital Management holding shares worth $109.1 million and ADAR1 Capital Management increasing its stake by 137%. argenx SE (NASDAQ:ARGX) saw 42 hedge fund holdings in Q1 2026 (down from 48 in Q4 2025), though heavily backed by major funds like VenBio Select Advisor (shares worth $927.8 million) and Citadel Investment Group (shares worth $197.1 million). Conclusion & what to watch next. Investors should watch whether the FDA requires an additional, standalone Phase 3 trial for Vyvgart in dermatomyositis, as well as regulatory submission timelines in both the U.S. and Greater China. Furthermore, monitor Zai Lab's commercial execution on its newer launches to curb ongoing operating losses. While we acknowledge the risk and potential of ARGX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ARGX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

Zai Lab posts $106.3M revenue in Q2 2026, misses estimates. 06 August 2026 11:27 AM PDT Summarize with AI You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to its research reports, in-depth technical and fundamental research. Learn more Zai Lab Limited generated total revenues of $106.3 million in the second quarter of 2026, missing expectations as it widened its net loss to $50.8 million. For investors, the revenue miss may raise concerns, but the ongoing development of its oncology and immunology pipeline signals potential for long-term growth. Key Highlights * Zai Lab Limited reported total revenues of $106.3 million for the second quarter of 2026, falling short of the $110.0 million seen the previous year and below market expectations. * Zai Lab's total revenue was $106.3 million in Q2 2026, contrasting with $110.0 million in the same quarter of the prior year. * Zai Lab continues to focus on advancing its oncology and immunology programs, with significant milestones approaching. Zai Lab Limited reported total revenues of $106.3 million for the second quarter of 2026, falling short of the $110.0 million seen the previous year and below market expectations. This disappointing performance highlights challenges faced in stabilizing product demand, despite year-over-year product revenue increasing by 11% compared to the first quarter of the year. Shares of Zai Lab are now down 5.1% over the past month, making investor confidence a key area to monitor as the firm seeks recovery. Financial Performance Overview Zai Lab's total revenue was $106.3 million in Q2 2026, contrasting with $110.0 million in the same quarter of the prior year. Product revenue, net came in at $105.8 million, down from $109.1 million year-over-year. Despite this decline, net product revenue grew 11% compared to Q1 2026, showcasing a recovery fueled by improved sales of ZEJULA and significant growth for VYVGART. The increase in expenses, specifically $61.8 million in R&D and $72.9 million in SG&A, contributed to a larger loss from operations of $76.5 million. The escalating losses necessitate scrutiny as Zai Lab aims to return to meaningful growth by 2027. Pipeline Developments and Catalyst Signals Zai Lab continues to focus on advancing its oncology and immunology programs, with significant milestones approaching. Zoci has garnered promising designations, including Orphan Drug Designation from the FDA and EMA for treating neuroendocrine carcinomas. These developments signal an ambitious timeline that could shape Zai Lab's growth trajectory. Short Interest Context As of mid-July 2026, Zai Lab's short position was 1% of shares outstanding, with an average cover time of 7.5 days, revealing a modestly optimistic sentiment among investors. The 22% decrease in short interest reflects market confidence, albeit the persistent losses may warrant caution. Market performance indicates Zai Lab shares are up 6.0% year-to-date, but the missed revenue target could prompt volatility. Investors will look for management's insights during today's conference call on the path forward. Analysis based on the Form 8-K filed 6 August 2026; figures verified against the filing and live market data. This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions. FAQs. Q: what were Zai Lab's earnings for Q2 2026? A: Zai Lab reported a net loss of $50.8 million for Q2 2026, translating to a loss of $0.46 per American Depositary Share. Q: What is Zai Lab's focus moving forward? A: Zai Lab is concentrating on advancing its oncology and immunology pipelines, with potential regulatory submissions expected in 2027. Q: How has Zai Lab's stock performed recently? A: Zai Lab shares are down 5.1% over the past month but are up 6.0% year-to-date, reflecting mixed investor sentiment amid revenue concerns. Download Free Report - Explore 3 Stock Ideas & Industry Insights Unlock 3 stock ideas and key industry insights in its free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice. All investments involve risk - consider independent advice before making any investment decisions. Disclaimer: